J&J To Launch CARTO XP In Japan
This article was originally published in PharmAsia News
Johnson & Johnson plans to launch CARTO XP, an electroanatomical mapping system to diagnose and treat irregular heart beat. Using imaging technology such as computer tomography, CARTO XP diagnoses IHB and treats it via catheter. The system also diagnoses and treats tachycardia cases, the most frequent cases among IHB patients. Priced at ¥60 million ($550,173), J&J expects CARTO XP to launch in January. The insurance reimbursement price for the catheter is yet to be decided. (Click here for more - may require subscription.
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.